Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 910
- 试验地点
- 8
- 主要终点
- The time to onset of hemopathy defined as the time between the date of birth and the date of diagnosis of an hemopathy.
研究概览
简要总结
This is a multicenter, interventional, historico-prospective cohort pilot study aimed at specifying the phenotype of subjects carrying a constitutional familial DDX41 mutation, with a view to eventually publishing oncogenetic recommendations for carriers of this mutation.
The main objective of the LUCID project is to assess the cumulative risk of hematological diseases as a function of age in DDX41 germline mutation carriers.
This study will be carried out in two stages:
Stage 1: Inclusion of index cases in an oncogenetic consultation (salivary test, completion of an health self-questionnaire and collection of contact details for the related cases).
Stage 2: Proposition of participation to family members, by correspondence, and determination of carrier or non-carrier status of the constitutional familial DDX41 mutation (based on a salivary test).
A maximum of 210 index case patients and 700 family member will be included in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Women or man aged ≥ 18 years old.
- •Personal history(s) of hemopathy or patient with hemopathy at the time of inclusion.
- •Patient with a tumor mutation of DDX41 with an allelic frequency (AF) ≥ 30% (with total depth of nucleotide position >300x: provide tumor molecular analysis report).
- •Special case of inclusion of deceased index cases: the DDX41 tumor mutation of interest must be accompanied by another somatic DDX41 mutation (the most frequent being p.R525H).
- •Or patient known to be a constitutional carrier of a DDX41 mutation confirmed after oncogenetic consultation (in this case, provide constitutional analysis report).
- •Patient (or beneficiary) agreeing to release results of oncogenetic report.
- •Patient (or beneficiary) agrees to communicate the contact details of his relatives and that they may be contacted by mail to participate in the LUCID study.
- •Patient affiliated to a Social Health Insurance in France.
- •Patient able to participate and willing to give informed consent prior performance of any study-related procedures.
排除标准
- •No history of hemopathy or no current hemopathy.
- •Patient (or beneficiary) unable to complete questionnaire for social or psychological reasons.
- •Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
- •Related cases (Family member):
- •Inclusion Criteria:
- •Women or man aged ≥ 18 years old.
- •Related to an index case included in the LUCID study.
- •Agreeing to carry out a scientific salivary test for the constitutional research of the DDX41 mutation.
- •Patient affiliated to a Social Health Insurance in France.
- •Patient able to participate and willing to give informed consent prior performance of any study-related procedures.
- •Exclusion Criteria:
- •Not applicable from version 2 of the protocol. Related in the 4th or 5th degree to an index case included in the LUCID study.
- •Person already identified as an index case in the LUCID study.
- •Person unable to complete questionnaire for social or psychological reasons.
- •Person who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
结局指标
主要结局
The time to onset of hemopathy defined as the time between the date of birth and the date of diagnosis of an hemopathy.
时间窗: 74 months after the study start date
次要结局
- Post-transplant relapse-free survival defined as the time between the date of transplantation and the date of all-cause relapse or death.(74 months after the study start date)